{"id": "patient_01_q0", "generated_text": "1: D: Vincristine : Not part of the current treatment regimen for Mrs. Sample's DLBCL.\n\nExplanation: The treatment regimen includes Polatuzumab vedotin (A), Rituximab (B), Cyc", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q1", "generated_text": "2-vessel CHD: Mrs. Sample has 3-vessel CHD.\nTo determine which of the given options is NOT accurate based on the provided information, let's analyze each option step by step:\n\nA: She has 2-vessel", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q2", "generated_text": "2: Multiple sclerosis\n\nThe patient diagnosed with multiple sclerosis is a 42-year-old woman with a history of recurrent, relapsing episodes. She presents with a variety of symptoms including a \"mass in the neck,\" numbness in both upper", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q3", "generated_text": "B:\n\nMrs. Sample takes Fingolimod 0.5mg, 1 capsule at bedtime, Note: Take a break as directed. The patient, diagnosed with relapsing-remitting multiple sclerosis that initially manifested aggressively, has", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q4", "generated_text": "D: 6 cycles of R-Pola-CHP\n\nThe oncology board recommends six cycles of the R-Pola-CHP regimen for Mrs. Sample, indicating the continuation of the current treatment plan without further modifications. This recommendation is based", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q5", "generated_text": "C: Thoracic vertebra 10\n\nBased on the provided information, the best option letter for the answer is:\n\n**C: Thoracic vertebra 10**. This corresponds to the text:\n\nThoracic vertebra: A mass", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q6", "generated_text": "01/09/2017, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement. Additional oral contrast was given using Gastrografin (d", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q7", "generated_text": "B:\n\nMrs. Sample received the following radiologic examinations in the order specified:\n\n1. **MR Brain (3D unenhanced + contrast) from 12/19/2016 at 10:30 AM", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q8", "generated_text": "1. C: The dose of Sertraline hydrochloride was increased from 50 mg to 100 mg. : The patient was given an additional 50 mg of Sertraline hydrochloride, bringing her", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q9", "generated_text": "3: A: The patient's cardiovascular risk was decreased, leading to a reduced number of cardiovascular medications at discharge. \n\nAnswer: 4: B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromor", "model_name": "Qwen/Qwen2.5-1.5B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
